Trial Profile
Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary) ; Cyclophosphamide; Etoposide; Granulocyte colony-stimulating factors
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms GRAALL-2014; GRAALL-2014/T; Graall-2014/T Atriall
- 12 Dec 2023 Results from ATRIALL sub-study comparing outcome to that of similar patients treated in same GRAALL-2014/T trial but without frontline NELA presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 23 Aug 2016 New trial record